21 January 2018 - Last year, Marathon Pharmaceuticals acquired a European muscular dystrophy drug, secured FDA approval, and jacked up the price 60 fold. 

Now, another biotech appears poised to use the same strategy. What can – or should – be done to stop it?

Superficially, this may look like a no-brainer, with a fairly obvious path forward: close the loopholes that allow this to occur, and punish future perpetrators. But although many drug pricing scandals get lumped together in the lay press, this particular example shows that the differences between them are important if we want to develop effective policies to improve drug access and affordability.

Read Forbes article